AAAAAA
Results: 1-25/58
Authors:
Verhoeven, AC
Boers, M
Koppele, JMT
van der Laan, WH
Markusse, HM
Geusens, P
van der Linden, S
Citation: Ac. Verhoeven et al., Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone, RHEUMATOLOG, 40(11), 2001, pp. 1231-1237
Authors:
Vignon, E
Garnero, P
Delmas, P
Avouac, B
Bettica, P
Boers, M
Ehrich, E
MacKillop, N
Rovati, L
Serni, U
Spector, T
Reginster, JY
Citation: E. Vignon et al., Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers, OSTEO CART, 9(4), 2001, pp. 289-293
Authors:
Verhagen, AP
de Vet, HCW
de Bie, RA
Boers, M
van den Brandt, PA
Citation: Ap. Verhagen et al., The art of quality assessment of RCTs included in systematic reviews, J CLIN EPID, 54(7), 2001, pp. 651-654
Authors:
Boers, M
Citation: M. Boers, Rheumatoid arthritis - Treatment of early disease, RHEUM DIS C, 27(2), 2001, pp. 405-414
Authors:
Verhoeven, AC
Boers, M
Koppele, JMT
van der Laan, WH
de Roos, J
van der Linden, S
Citation: Ac. Verhoeven et al., Reliability of spot samples for assessment of urinary excretion of pyridinoline in patients with rheumatoid arthritis, CLIN EXP RH, 19(1), 2001, pp. 78-80
Authors:
Boers, M
Citation: M. Boers, Methodology of combination trials, SPR SEM IMM, 23(1-2), 2001, pp. 27-33
Authors:
Boers, M
Citation: M. Boers, Bias in its coat of many colors, J RHEUMATOL, 28(8), 2001, pp. 1747-1748
Authors:
Welch, V
Singh, G
Strand, V
Fries, J
Boers, M
Ramey, D
Day, RO
Brooks, P
Tugwell, P
Clinch, J
Kristjansson, B
Citation: V. Welch et al., Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index, J RHEUMATOL, 28(5), 2001, pp. 1188-1191
Authors:
Verburg, RJ
Sont, JK
Vlieland, TPMV
Landewe, RB
Boers, M
Kievit, J
van Laar, JM
Citation: Rj. Verburg et al., High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis, J RHEUMATOL, 28(4), 2001, pp. 719-727
Authors:
Strand, V
Lassere, M
van der Heijde, D
Johnson, K
Boers, M
Citation: V. Strand et al., Recent rheumatoid arthritis clinical trials using radiographic endpoints -Updated research agenda, J RHEUMATOL, 28(4), 2001, pp. 887-889
Authors:
Lassere, MND
van der Heijde, D
Johnson, KR
Boers, M
Edmonds, J
Citation: Mnd. Lassere et al., Reliability of measures of disease activity and disease damage in rheumatoid arthritis: Implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials, J RHEUMATOL, 28(4), 2001, pp. 892-903
Authors:
Bruynesteyn, K
van der Heijde, D
Boers, M
Lassere, M
Boonen, A
Edmonds, J
Houben, H
Paulus, H
Peloso, P
Saudan, A
van der Linden, S
Citation: K. Bruynesteyn et al., Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: Preliminary results of a validation study with clinical experts, J RHEUMATOL, 28(4), 2001, pp. 904-910
Authors:
Lassere, MND
van der Heijde, D
Johnson, K
Bruynesteyn, K
Molenaar, E
Boonen, A
Verhoeven, A
Emery, P
Boers, M
Citation: Mnd. Lassere et al., Robustness and generalizability of smallest detectable difference in radiological progression, J RHEUMATOL, 28(4), 2001, pp. 911-913
Authors:
van der Heijde, D
Lassere, M
Edmonds, J
Kirwan, J
Strand, V
Boers, M
Citation: D. Van Der Heijde et al., Minimal clinically important difference in plain films in RA: Group discussions, conclusions, and recommendations, J RHEUMATOL, 28(4), 2001, pp. 914-917
Authors:
Gabriel, S
Drummond, M
Coyle, D
Suarez-Almazor, ME
Ruff, B
Guillemin, F
Bombardier, C
Boers, M
Maetzel, A
Ruof, J
Cranney, A
Marentette, M
Tugwell, P
Citation: S. Gabriel et al., OMERACT 5 Economics Working Group: Summary, recommendations, and research agenda, J RHEUMATOL, 28(3), 2001, pp. 670-673
Authors:
Tugwell, P
Boers, M
Brooks, PM
Simon, L
Strand, CV
Citation: P. Tugwell et al., OMERACT 5. International Consensus Conference on Outcome Measures in Rheumatology - Introduction, J RHEUMATOL, 28(2), 2001, pp. 395-397
Authors:
Beaton, DE
Bombardier, C
Katz, JN
Wright, JG
Wells, G
Boers, M
Strand, V
Shea, B
Citation: De. Beaton et al., Looking for important change/differences in studies of responsiveness, J RHEUMATOL, 28(2), 2001, pp. 400-405
Authors:
Wells, G
Beaton, D
Shea, B
Boers, M
Simon, L
Strand, V
Brooks, P
Tugwell, P
Citation: G. Wells et al., Minimal clinically important differences: Review of methods, J RHEUMATOL, 28(2), 2001, pp. 406-412
Authors:
Wells, G
Anderson, J
Beaton, D
Bellamy, N
Boers, M
Bombardier, C
Breedveld, F
Carr, A
Cranney, A
Dougados, M
Felson, D
Kirwan, J
Schiff, M
Shea, B
Simon, L
Smolen, J
Strand, V
Tugwell, P
van Riel, P
Welch, VA
Citation: G. Wells et al., Minimal clinically important difference module: Summary, recommendations, and research agenda, J RHEUMATOL, 28(2), 2001, pp. 452-454
Authors:
van Tinteren, H
Hoekstra, OS
Smit, EF
Verboom, P
Boers, M
Citation: H. Van Tinteren et al., Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography, CONTR CL TR, 22(1), 2001, pp. 89-98
Authors:
Moll, AC
Imhof, SM
Schouten-VanMeeteren, YN
Kuik, DJ
Hofman, P
Boers, M
Citation: Ac. Moll et al., Second primary tumors in hereditary retinoblastoma: A register-based study, 1945-1997 - Is there an age effect on radiation-related risk?, OPHTHALMOL, 108(6), 2001, pp. 1109-1114
Authors:
Boers, M
Citation: M. Boers, NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection, LANCET, 357(9264), 2001, pp. 1222-1223
Authors:
Hooft, L
Hoekstra, OS
Deville, W
Lips, P
Teule, GJJ
Boers, M
van Tulder, MW
Citation: L. Hooft et al., Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomographyin the follow-up of papillary or follicular thyroid cancer, J CLIN END, 86(8), 2001, pp. 3779-3786
Authors:
Boers, M
Verhoeven, AC
van der Linden, S
Citation: M. Boers et al., American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement, ARTH RHEUM, 44(5), 2001, pp. 1052-1055
Authors:
Boers, M
Citation: M. Boers, Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial, ARTH RHEUM, 44(11), 2001, pp. 2703-2704